COST-EFFECTIVENESS OF A NEW FIXED-DOSE COMBINATION OF DUTASTERIDE AND TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IN QUEBEC, CANADA

被引：0
|
作者：
Ismaila, A. [1 ]
Posnett, J. [2 ]
Walker, A. [2 ]
Sayani, A. [1 ]
Laroche, B. [3 ]
Nickel, J. C. [4 ]
Robson, R. C. [1 ]
Su, Z. [1 ]
机构：
[1] GlaxoSmithKline Inc, Mississauga, ON, Canada
[2] Heron Evidence Dev Ltd, Luton, Beds, England
[3] Hop St Francois Assise, Quebec City, PQ, Canada
[4] Queens Univ, Kingston, ON, Canada
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A194 / A194
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF ADDING A NEW FIXED-DOSE COMBINATION THERAPY OF DUTASTERIDE AND TAMSULOSIN TO THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IN QUEBEC, CANADA
    Ismaila, A.
    Posnett, J.
    Walker, A.
    Sayani, A.
    Robson, R. C.
    Su, Z.
    VALUE IN HEALTH, 2012, 15 (04) : A193 - A193
  • [2] Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada
    Sayani, Amyn
    Ismaila, Afisi
    Walker, Anna
    Posnett, John
    Laroche, Bruno
    Nickel, J. Curtis
    Su, Zhen
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (1-2): : E1 - E7
  • [3] A COST-MINIMIZATION ANALYSIS OF A NEW FIXED-DOSE COMBINATION OF DUTASTERIDE AND TAMSULOSIN COMPARED TO CONCOMITANT ADMINISTRATION OF BOTH MONOTHERAPIES FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IN QUEBEC, CANADA
    Sayani, A.
    Ismaila, A.
    Posnett, J.
    Walker, A.
    Laroche, B.
    Nickel, J. C.
    Su, Z.
    VALUE IN HEALTH, 2013, 16 (03) : A182 - A182
  • [4] Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia
    Dimitropoulos, Konstantinos
    Gravas, Stavros
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 19 - 28
  • [5] DUTASTERIDE/TAMSULOSIN FIXED-DOSE COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC ENLARGEMENT
    Ismail, M.
    Hashim, H.
    DRUGS OF TODAY, 2012, 48 (01) : 17 - 24
  • [6] COST-EFFECTIVENESS ANALYSIS OF DUTASTERIDE, TAMSULOSIN AND COMBINATION THERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    Bang, S., I
    Hay, J.
    VALUE IN HEALTH, 2010, 13 (03) : A78 - A78
  • [7] Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
    Barkin, Jack
    PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 483 - 490
  • [8] Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial
    Ismaila, Afisi
    Walker, Anna
    Sayani, Amyn
    Laroche, Bruno
    Nickel, J. Curtis
    Posnett, John
    Su, Zhen
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2013, 7 (5-6): : E393 - E401
  • [9] Cost-Effectiveness of the Combination Therapy of Dutasteride and Tamsulosin in the Treatment of Benign Prostatic Hyperlasia in Spain
    Antonanzas, F.
    Brenes, F.
    Molero, J. M.
    Fernandez-Pro, A.
    Huerta, A.
    Palencia, R.
    Cozar, J. M.
    ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (02): : 65 - 71
  • [10] Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK
    Walker, Anna
    Doyle, Scott
    Posnett, John
    Hunjan, Manjit
    BJU INTERNATIONAL, 2013, 112 (05) : 638 - 646
12345